RPL22L1, a novel candidate oncogene promotes temozolomide resistance by activating STAT3 in glioblastoma

Aggressiveness and drug resistance are major challenges in the clinical treatment of glioblastoma (GBM). Our previously research reported a novel candidate oncogene ribosomal protein L22 like 1 (RPL22L1). The aim of this study was to elucidate the potential role and mechanism of RPL22L1 in progressi...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yunping, Mu, Yu, Guan, Qing, Li, Chenlong, Zhang, Yangong, Xu, Yinzhi, Zhou, Chong, Guo, Ying, Ma, Yanan, Zhao, Meiqi, Ji, Guohua, Liu, Peng, Sun, Donglin, Sun, Haiming, Wu, Nan, Jin, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10662465/
https://www.ncbi.nlm.nih.gov/pubmed/37985768
http://dx.doi.org/10.1038/s41419-023-06156-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10662465/
https://www.ncbi.nlm.nih.gov/pubmed/37985768
http://dx.doi.org/10.1038/s41419-023-06156-6

Ejemplares similares